MedPath

Cancer therapy with vaccination using HLA-A02-restricted peptide from RNF43: a phase I study in patients with unresectable colorectal cancer

Phase 1
Conditions
unresectable colorectal cancer
Registration Number
JPRN-UMIN000000701
Lead Sponsor
Institute of Medical Science The University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
6
Inclusion Criteria

Not provided

Exclusion Criteria

pregnancy uncontroled infection uncontroled cerebral metastasis etc,

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath